NCT07552649Not yet recruitingPhase 2
Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia
MATCH-Treg: Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia
Source: ClinicalTrials.gov · Last updated 27 Apr 2026
Brief summary (registry, in English)
The study is a multicentric, interventional study that evaluates the efficacy of allogeneic HLA-matched allo-HSCT consisting of myeloablative conditioning coupled with donor Treg/Tcon adoptive immunotherapy for high-risk AML patients.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- First submitted
- 20 Apr 2026
- Start date
- Apr 2026
- Primary completion date
- Apr 2028
- Lead sponsor
- Antonio Pierini
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT07552649
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 28
- From Apr 2026 to the primary completion date, Apr 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior allo-HSCT
Other illness
- Active disease at transplant (\> 5% bone marrow infiltration)
- Unacceptable lung, liver, kidney, and/or heart function and presence of relevant psychiatric diseases according to clinical judgment
- Uncontrolled bacterial, viral, or fungal infections at time of enrollment
Age
- Age \< 18 years or \> 70 years
Other
- AML with favorable genetic abnormalities
- AML with intermediate genetic risk with MRD negativity
- Availability of a haploidentical or matched unrelated donor (MUD)
- ECOG \> 2
- Pregnancy
- No signature of the informed consent
Who the study is looking for
- Diagnosis of AML with adverse genetic mutations in Complete Remission (CR) or incomplete (i) CR according to ELN 2022 recommendations with or without MRD positivity at the time of the HSCT procedure;
- Diagnosis of AML with intermediate genetic mutations in Complete remission (CR) or incomplete (i) CR according to ELN 2022 with MRD positivity at the time of the transplant;
- Fitness to undergo allo-HCT with myeloablative conditioning regimens according to center policy;
- Availability of a family HLA-matched hematopoietic stem cell donor suitable to be treated with G-CSF (10 mcg/kg/die) for a maximum of 7 days and able to tolerate 2 or more leukaphereses.
- Age ≥ 18 and ≤ 70 years
- ECOG ≤ 2
- HCT-CI ≤ 4
- Signature of the informed consent
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Azienda Ospedaliera di Perugia;Ospedale S. Maria della Misericordia Coordinator of this site? Confirm its status | Perugia | Italy | Unknown status |
| Presidio Ospedaliero Pescara - Azienda Sanitaria Locale di Pescara Coordinator of this site? Confirm its status | Pescara | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.